ATG9A and neoplasm: Remarkably, while CSF1R inhibition alone had no effect on sgGAL4 or sgATG9A tumor size (Fig. 9G), 93.3% (28/30) of mice bearing ATG9A KO tumors were completely eradicated when combined with Trastuzumab and CSF1Ri, compared to 0% in the control group (Fig. 9H, I).